Cargando…

Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market

This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim.

Detalles Bibliográficos
Autores principales: Dean, Emma Boswell, Bond, Amelia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796923/
https://www.ncbi.nlm.nih.gov/pubmed/35977178
http://dx.doi.org/10.1001/jamahealthforum.2021.2634
_version_ 1784641425001938944
author Dean, Emma Boswell
Bond, Amelia M.
author_facet Dean, Emma Boswell
Bond, Amelia M.
author_sort Dean, Emma Boswell
collection PubMed
description This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim.
format Online
Article
Text
id pubmed-8796923
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-87969232022-02-07 Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market Dean, Emma Boswell Bond, Amelia M. JAMA Health Forum Research Letter This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim. American Medical Association 2021-09-17 /pmc/articles/PMC8796923/ /pubmed/35977178 http://dx.doi.org/10.1001/jamahealthforum.2021.2634 Text en Copyright 2021 Dean EB et al. JAMA Health Forum. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Dean, Emma Boswell
Bond, Amelia M.
Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market
title Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market
title_full Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market
title_fullStr Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market
title_full_unstemmed Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market
title_short Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market
title_sort changes in medicare part b spending for biologic drugs after biosimilar entry into the market
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796923/
https://www.ncbi.nlm.nih.gov/pubmed/35977178
http://dx.doi.org/10.1001/jamahealthforum.2021.2634
work_keys_str_mv AT deanemmaboswell changesinmedicarepartbspendingforbiologicdrugsafterbiosimilarentryintothemarket
AT bondameliam changesinmedicarepartbspendingforbiologicdrugsafterbiosimilarentryintothemarket